APHINITY Trial for HER2+ Breast Cancer

APHINITY Update - Pertuzumab in HER2+ breast cancerПодробнее

Smilow Shares: Breast Cancer Education Series (CME) - Treatment Advances/Clinical TrialsПодробнее

Lightning Updates | 2023 Best of Breast ConferenceПодробнее

Sequencing Treatment Options in HER2 Positive Breast Cancer: 2023 Best of Breast ConferenceПодробнее

SABCS 2023 HER2+ Breast Cancer Highlights – APHINITY Sub-analysis, KATHERINE update, HER2CLIMB-02Подробнее

3-year DFS in randomized trials of chemotherapy and HER2-targeted therapyПодробнее

Pertuzumab, trastuzumab and cyclophosphamide in older patients with HER2+ breast cancerПодробнее

Adjuvant T-DM1 for HER 2+ Breast Cancer: Critical Data From The KATHERINE StudyПодробнее

Anti-HER2 Therapy in breast Cancer - OverviewПодробнее

Neoadjuvant chemotherapy for breast cancer - Time to rethink. 27Jul22Подробнее

HER2+ Breast Cancer Case Panel Discussion | 2022 Best of Breast ConferenceПодробнее

Study comparing margetuximab combinations to trastuzumab combinations in HER2-positive breast cancerПодробнее

New & Supporting Data for Optimizing Therapy in HER2+ Breast Cancer | Dr. Irene and Dr. VogelПодробнее

New & Supporting Data for Optimizing Therapy in HER2+ Breast Cancer | Dr. Kaklamani and Dr. O’ReganПодробнее

2022 West Oncology Conference | Breast Cancers | Early-StageПодробнее

New & Supporting Data for Optimizing Therapy in HER2+ Breast Cancer | Dr. Meisel & Dr. SolimanПодробнее

Outcomes from ADAPT-HR-/HER2+ evaluating dual HER2 blockadeПодробнее

Breast Cancer Management in North Carolina: Updates for 2021 - Y. Abdou - 20210623Подробнее

New & Supporting Data for Optimizing Therapy in HER2+ Breast Cancer | Dr. Mahtani & Dr. SchwartzbergПодробнее

Biomarker analysis of the NeoALTTO trial provides oncofertility insight for younger breast cance...Подробнее